Glenmark Pharma US Unit Introduces Generic Vancomycin Injection in the US Market

Glenmark Pharmaceuticals Inc., the U.S. subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Vancomycin Hydrochloride for Injection USP. The drug is being introduced in three single-dose vial strengths: 750 mg, 1.25 g, and 1.5 g single-dose vials. It is intended for intravenous administration and is used in the treatment of systemic bacterial infections.

As of 10:49 AM on April 2, 2025, Glenmark Pharmaceuticals share price is trading at ₹1526.10, a 1.12% increase for the day, up 14.61% over the past month, but down 8.47% over the past six months.

Bioequivalence and Reference Drug

The launched version is bioequivalent and therapeutically equivalent to the reference listed drug (RLD) Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial, and 1.5 g/vial, developed by Mylan Laboratories Limited under NDA 209481. Glenmark’s product is approved only for the indications listed on its approved label.

Sales Data

According to data mentioned in reports, for the 12-month period ending January 2025, the total market for Vancomycin Hydrochloride for Injection (across the three strengths and all available therapeutic equivalents) recorded sales of approximately $39.3 million, or ₹336.47 crore​.

Availability in the US Market

The product will be marketed across the United States and is now part of Glenmark’s institutional portfolio. It is manufactured in compliance with U.S. FDA regulations and is available for use in hospital and clinical settings.

Marc Kikuchi, President & Business Head, North America, said, “We are excited to announce the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial), adding another quality product to our institutional portfolio.”

Company Overview

Glenmark Pharmaceuticals Ltd is a research-led pharmaceutical company headquartered in Mumbai, India. The company operates across branded, generics, and over-the-counter (OTC) segments, with a presence in more than 80 countries. Glenmark runs 11 manufacturing facilities across four continents. 

Conclusion

The launch of Vancomycin Hydrochloride for Injection by Glenmark Pharmaceuticals Inc., USA expands the availability of generic alternatives within the U.S. institutional market. By introducing therapeutically equivalent dosage forms to an established product, the company enters a segment with existing demand and measurable annual sales.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.